Hemab Therapeutics (NASDAQ:COAG) Shares Down 8% – What’s Next?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s stock price dropped 8% on Wednesday . The stock traded as low as $33.78 and last traded at $33.78. Approximately 56,274 shares were traded during trading, a decline of 78% from the average session volume of 260,032 shares. The stock had previously closed at $36.73.

Analyst Ratings Changes

A number of equities analysts have weighed in on COAG shares. Evercore assumed coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock. Jefferies Financial Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $39.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Hemab Therapeutics in a report on Friday, June 26th. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price for the company. Finally, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.40.

Hemab Therapeutics Price Performance

The company’s 50 day moving average price is $27.82. The stock has a market capitalization of $1.45 billion and a PE ratio of -1.29.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the transaction, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. This represents a 0.96% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have acquired 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.